Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas

Author:

Liu Zhen,Hong Xuanke,Wang Linglong,Ma Zeyu,Guan Fangzhan,Wang Weiwei,Qiu Yuning,Zhang Xueping,Duan Wenchao,Wang Minkai,Sun Chen,Zhao Yuanshen,Duan Jingxian,Sun Qiuchang,Liu Lin,Ding Lei,Ji Yuchen,Yan Dongming,Liu Xianzhi,Cheng Jingliang,Zhang Zhenyu,Li Zhi-Cheng,Yan Jing

Abstract

Abstract Background We aimed to develop machine learning models for prediction of molecular subgroups (low-risk group and intermediate/high-risk group) and molecular marker (KIAA1549-BRAF fusion) of pediatric low-grade gliomas (PLGGs) based on radiomic features extracted from multiparametric MRI. Methods 61 patients with PLGGs were included in this retrospective study, which were divided into a training set and an internal validation set at a ratio of 2:1 based on the molecular subgroups or the molecular marker. The patients were classified into low-risk and intermediate/high-risk groups, BRAF fusion positive and negative groups, respectively. We extracted 5929 radiomic features from multiparametric MRI. Thereafter, we removed redundant features, trained random forest models on the training set for predicting the molecular subgroups or the molecular marker, and validated their performance on the internal validation set. The performance of the prediction model was verified by 3-fold cross-validation. Results We constructed the classification model differentiating low-risk PLGGs from intermediate/high-risk PLGGs using 4 relevant features, with an AUC of 0.833 and an accuracy of 76.2% in the internal validation set. In the prediction model for predicting KIAA1549-BRAF fusion using 4 relevant features, an AUC of 0.818 and an accuracy of 81.0% were achieved in the internal validation set. Conclusions The current study demonstrates that MRI radiomics is able to predict molecular subgroups of PLGGs and KIAA1549-BRAF fusion with satisfying sensitivity. Trial registration This study was retrospectively registered at clinicaltrials.gov (NCT04217018).

Funder

the National Key R&D Program of China

the Science and Technology Program of Henan Province

the National Natural Science Foundation of China

the Key-Area Research and Development Program of Guangdong Province

the Excellent Youth Talent Cultivation Program of Innovation in Health Science and Technology of Henan Province

the Key Program of Medical Science and Technique Foundation of Henan Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3